Canagliflozin Description

Canagliflozin (INN, barter name Invokana) is a biologic for the analysis of blazon 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed beneath authorization by Janssen, a analysis of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium-glucose carriage protein (SGLT2), which is amenable for at atomic 90% of the glucose reabsorption in the kidney. Blocking this agent causes claret glucose to be alone through the urine.
Canagliflozin is the additional sodium-glucose co-transporter inhibitor to be accustomed in Australia. Like dapagliflozin (Aust Prescr 2013;36:174-9 ).